Evidence map›Paper›PMID 28103614›Full record

ArticleBritish journal of cancer2017

Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.

Siddhartha P Kar, Emily Adler, Jonathan Tyrer, Dennis Hazelett, Hoda Anton-Culver, Elisa V Bandera, Matthias W Beckmann, Andrew Berchuck, Natalia Bogdanova, Louise Brinton and 76 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Comparative transcriptomic analysis of ratNeural regeneration research · 2021
    Article
  6. PAX8, an Emerging Player in Ovarian Cancer.Advances in experimental medicine and biology · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

86 authors at 20 institutions in 11 countries.

Siddhartha P KarDepartment of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
Emily AdlerDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Jonathan TyrerDepartment of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
Dennis HazelettBioinformatics and Computational Biology Research Center, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Hoda Anton-CulverDepartment of Epidemiology, Director of Genetic Epidemiology Research Institute, UCI Center for Cancer Genetics Research & Prevention, School of Medicine, University of California Irvine, Irvine, CA 92697, USA.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Matthias W BeckmannUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Universitaetsstrasse 21-23, Erlangen 91054, Germany.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA.
Natalia BogdanovaRadiation Oncology Research Unit, Hannover Medical School, Hannover 30625, Germany.
Louise BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Ralf ButzowDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki 00100, Finland.
Ian CampbellCancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002, Australia.
Karen CartyThe Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK.
Jenny Chang-ClaudeGerman Cancer Research Center, Division of Cancer Epidemiology, Heidelberg 69120, Germany.
Linda S CookDivision of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA 02215, USA.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Agnieszka Dansonka-MieszkowskaDepartment of Pathology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02-781, Poland.
Jennifer Anne DohertyDepartment of Epidemiology, The Geisel School of Medicine-at Dartmouth, Hanover, NH 03756, USA.
Thilo DörkGynaecology Research Unit, Hannover Medical School, Hannover 30625, Germany.
Matthias DürstDepartment of Gynecology, Jena-University Hospital-Friedrich Schiller University, Jena 07737, Germany.
Diana EcclesFaculty of Medicine, University of Southampton, Southampton SO16 5YA, UK.
Peter A FaschingUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Universitaetsstrasse 21-23, Erlangen 91054, Germany.
James FlanaganDepartment of Surgery & Cancer, Imperial College London, London SW7 2AZ, UK.
Aleksandra Gentry-MaharajDepartment of Women's Cancer, Institute for Women's Health, University College London, London W1T 7DN, UK.
Rosalind GlasspoolThe Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK.
Ellen L GoodeDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MI 55905, USA.
Marc T GoodmanCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jacek GronwaldInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-001, Poland.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/ Knappschaft GmbH, Essen 45136, Germany.
Michelle A T HildebrandtDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Estrid HøgdallDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen 2100, Denmark.
Claus K HøgdallThe Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark.
David G HuntsmanBritish Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver General Hospital, BC Cancer Agency and University of British Columbia, Vancouver, BC V5Z 1L3, Canada.
Allan JensenDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen 2100, Denmark.
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Linda E KelemenDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC 29435, USA.
Lambertus A KiemeneyRadboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen 6500 HB, The Netherlands.
Susanne K KjaerDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen 2100, Denmark.
Jolanta KupryjanczykDepartment of Pathology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02-781, Poland.
Diether LambrechtsVesalius Research Center, VIB, Leuven 3000, Belgium.
Douglas A LevineGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Qiyuan LiDepartment of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jolanta LissowskaDepartment of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02-781, Poland.
Karen H LuDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jan LubińskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-001, Poland.
Leon F A G MassugerRadboud University Medical Center, Radboud Institute for Molecular Life Sciences, Department of Gynaecology, Nijmegen 6500 HB, The Netherlands.
Valerie McGuireDepartment of Health Research and Policy-Epidemiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Iain McNeishInstitute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow G12 0YN, UK.
Usha MenonDepartment of Women's Cancer, Institute for Women's Health, University College London, London W1T 7DN, UK.
Francesmary ModugnoDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Alvaro N MonteiroDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Kirsten B MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Roberta B NessThe University of Texas School of Public Health, Houston, TX 77030, USA.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki 00100, Finland.
James PaulThe Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK.
Celeste L PearceDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Tanja PejovicDepartment of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR 97239, USA.
Jennifer B PermuthDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Catherine PhelanDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Elizabeth M PooleChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
Susan J RamusFaculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Harvey A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT 06510, USA.
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Helga B SalvesenDepartment of Gynecology and Obstetrics, Haukeland University Horpital, Bergen 5058, Norway.
Joellen M SchildkrautDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Thomas A SellersDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Mark ShermanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Nadeem SiddiquiDepartment of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow G4 0SF, UK.
Weiva SiehDepartment of Health Research and Policy-Epidemiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Honglin SongDepartment of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
Melissa SoutheyGenetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne, VIC 3002, Australia.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA 02215, USA.
Shelley S TworogerChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
Christine WalshWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Alice S WhittemoreDepartment of Health Research and Policy-Epidemiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Hannah YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Wei ZhengDivision of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Medicine, Nashville, TN 37232, USA.
Argyrios ZiogasDepartment of Epidemiology, University of California Irvine, Irvine, CA 92697, USA.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Simon A GaytherSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Paul D P PharoahDepartment of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
Kate LawrensonSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cedars-Sinai Medical Center · USMoffitt Cancer Center · USUniversity of Cambridge · GBBeatson West of Scotland Cancer Centre · GBStanford University · USThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity of Southern California · USBrigham and Women's Hospital · USDanish Cancer Society · DKDivision of Cancer Epidemiology and GeneticsDuke Medical Center · USHarvard University · USInternational Hereditary Cancer Center · PLMedizinische Hochschule Hannover · DENational Cancer Institute · USRigshospitalet · DKThe University of Melbourne · AUThe University of Texas MD Anderson Cancer Center · USUniversitätsklinikum Erlangen · DEUniversity College London · GB

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Jian Ouyang · 2009 to 2026
$42.7M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Northern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6M
Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK 13086Cancer Research UK 16561Medical Research Council G0501974NCATS NIH HHS UL1 TR001863NCI NIH HHS K07 CA080668NCI NIH HHS K07 CA092044NCI NIH HHS K07 CA095666NCI NIH HHS K07 CA143047NCI NIH HHS K22 CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC035137NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA138313NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R00 CA184415NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA063682NCI NIH HHS R01 CA064277NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA080742NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA087696NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA106414NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01 CA136924NCI NIH HHS R01 CA149429NCI NIH HHS R01 CA211707NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R37 CA070867NCI NIH HHS U01 CA069417NCI NIH HHS U19 CA148112NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA182910NCI NIH HHS UM1 CA186107NCRR NIH HHS M01 RR000056
6 · The paper itself

Abstract

backgroundGenome-wide association studies (GWAS) have identified 18 loci associated with serous ovarian cancer (SOC) susceptibility but the biological mechanisms driving these findings remain poorly characterised. Germline cancer risk loci may be enriched for target genes of transcription factors (TFs) critical to somatic tumorigenesis.

methodsAll 615 TF-target sets from the Molecular Signatures Database were evaluated using gene set enrichment analysis (GSEA) and three GWAS for SOC risk: discovery (2196 cases/4396 controls), replication (7035 cases/21 693 controls; independent from discovery), and combined (9627 cases/30 845 controls; including additional individuals).

resultsThe PAX8-target gene set was ranked 1/615 in the discovery (P

conclusionsPutative PAX8 target genes are enriched for common SOC risk variants. This finding from our agnostic evaluation is of particular interest given that PAX8 is well-established as a specific marker for the cell of origin of SOC.

Indexed as

Gene AmplificationGenetic LociGenetic Predisposition to DiseaseCarcinoma, Ovarian EpithelialCase-Control StudiesCell Line, TumorCell Transformation, NeoplasticCystadenocarcinoma, SerousFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenome-Wide Association StudyHumansMeta-Analysis as TopicMicroarray AnalysisNeoplasms, Glandular and Epithelial

Identifiers

PMID28103614
PMCPMC5318969
OpenAlexW2577415758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.